Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 18/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913167 | 0.86 | NR3C2 (0.53) | NR3C2PKMRAB9A | |
| SCHEMBL3503006 | 0.85 | NR3C2 (0.60) | NR3C2 | |
| SCHEMBL27827424 | 0.85 | NR3C2 (0.56) | NR3C2PKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5908624 | 0.83 | NR3C2 (0.61) | NR3C2 | |
| SCHEMBL5778556 | 0.81 | NR3C2 (0.59) | NR3C2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9934078 | 0.81 | NR3C2 (0.51) | NR3C2PKMRAB9A | |
| SCHEMBL27083330 | 0.81 | LOXL2 (0.59) | NR3C2PKM | |
| SCHEMBL4943008 | 0.81 | NR3C2 (0.51) | NR3C2PKMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5908475 | 0.80 | NR3C2 (0.58) | NR3C2 | |
| SCHEMBL2562571 | 0.80 | NR3C2 (0.50) | NR3C2PKMNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10144721-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2018-12-04 | — | — | US | disclosed |
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | disclosed |
| US-20160115152-A1 | Novel Compounds | RESPIVERT LTD. (GB) | 2016-04-28 | — | — | US | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2011124923-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2350049-A2 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115152-A1 | Novel Compounds | ESRRA, ESRRB, LTB4R | NR3C2 59/4885PKM 2543/4885NPC1 1033/4885 |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | NR3C2 254/4885PKM 226/4885NPC1 2423/4885 |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | NR3C2 2374/4885PKM 3759/4885NPC1 2860/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | NR3C2 84/4885PKM 778/4885NPC1 3170/4885 |
| US-10144721-B2 | P38 MAP kinase inhibitors | MAPK1, MAP3K1, MAP3K8 | NR3C2 144/4885PKM 463/4885NPC1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.